Alpha 2.0
Login Register
» Articles » PMID: 31019898

Objective Response by MRECIST Is an Independent Prognostic Factor of Overall Survival in Systemic Therapy for Hepatocellular Carcinoma

Overview
Journal Liver Cancer
Date 2019 Apr 26
PMID 31019898
Citations 10
Authors
Masatoshi Kudo
Affiliations
Soon will be listed here.
Citing Articles

Implications of the TACTICS Trial: Establishing the New Concept of Combination/Sequential Systemic Therapy and Transarterial Chemoembolization to Achieve Synergistic Effects.

Kudo M Liver Cancer. 2023; 11(6):487-496.

PMID: 36589725 PMC: 9801179. DOI: 10.1159/000527404.

Study on the changes of CT texture parameters before and after HCC treatment in the efficacy evaluation and survival predication of patients with HCC.

Zhou W, Lv Y, Hu X, Luo Y, Li J, Zhu H Front Oncol. 2022; 12:957737.

PMID: 36387217 PMC: 9650244. DOI: 10.3389/fonc.2022.957737.

Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma.

Amioka K, Kawaoka T, Kosaka M, Johira Y, Shirane Y, Miura R Cancers (Basel). 2022; 14(2).

PMID: 35053484 PMC: 8774012. DOI: 10.3390/cancers14020320.

Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma.

Yang Z, Suda G, Maehara O, Ohara M, Yoshida S, Hosoda S Cancers (Basel). 2022; 14(1).

PMID: 35008398 PMC: 8750627. DOI: 10.3390/cancers14010232.

Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.

Koroki K, Kanogawa N, Maruta S, Ogasawara S, Iino Y, Obu M Liver Cancer. 2021; 10(5):473-484.

PMID: 34721509 PMC: 8527907. DOI: 10.1159/000515552.

References
1.
Edeline J, Boucher E, Rolland Y, Vauleon E, Pracht M, Perrin C . Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer. 2011; 118(1):147-56. DOI: 10.1002/cncr.26255. View
2.
Ronot M, Bouattour M, Wassermann J, Bruno O, Dreyer C, Larroque B . Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib. Oncologist. 2014; 19(4):394-402. PMC: 3983809. DOI: 10.1634/theoncologist.2013-0114. View
3.
Arizumi T, Ueshima K, Chishina H, Kono M, Takita M, Kitai S . Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib. Dig Dis. 2014; 32(6):705-10. DOI: 10.1159/000368006. View
4.
Vincenzi B, Di Maio M, Silletta M, DOnofrio L, Spoto C, Piccirillo M . Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis. PLoS One. 2015; 10(7):e0133488. PMC: 4521926. DOI: 10.1371/journal.pone.0133488. View
5.
Takada J, Hidaka H, Nakazawa T, Kondo M, Numata K, Tanaka K . Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma. BMC Res Notes. 2015; 8:609. PMC: 4624170. DOI: 10.1186/s13104-015-1565-2. View